308 related articles for article (PubMed ID: 23340294)
1. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.
Schott AF; Landis MD; Dontu G; Griffith KA; Layman RM; Krop I; Paskett LA; Wong H; Dobrolecki LE; Lewis MT; Froehlich AM; Paranilam J; Hayes DF; Wicha MS; Chang JC
Clin Cancer Res; 2013 Mar; 19(6):1512-24. PubMed ID: 23340294
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.
Cook N; Basu B; Smith DM; Gopinathan A; Evans J; Steward WP; Palmer D; Propper D; Venugopal B; Hategan M; Anthoney DA; Hampson LV; Nebozhyn M; Tuveson D; Farmer-Hall H; Turner H; McLeod R; Halford S; Jodrell D
Br J Cancer; 2018 Mar; 118(6):793-801. PubMed ID: 29438372
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
Zhang CC; Yan Z; Zong Q; Fang DD; Painter C; Zhang Q; Chen E; Lira ME; John-Baptiste A; Christensen JG
Stem Cells Transl Med; 2013 Mar; 2(3):233-42. PubMed ID: 23408105
[TBL] [Abstract][Full Text] [Related]
4. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
Cui D; Dai J; Keller JM; Mizokami A; Xia S; Keller ET
Clin Cancer Res; 2015 Oct; 21(20):4619-29. PubMed ID: 26202948
[TBL] [Abstract][Full Text] [Related]
5. An accessible pharmacodynamic transcriptional biomarker for notch target engagement.
Tanis KQ; Podtelezhnikov AA; Blackman SC; Hing J; Railkar RA; Lunceford J; Klappenbach JA; Wei B; Harman A; Camargo LM; Shah S; Finney EM; Hardwick JS; Loboda A; Watters J; Bergstrom DA; Demuth T; Herman GA; Strack PR; Iannone R
Clin Pharmacol Ther; 2016 Apr; 99(4):370-80. PubMed ID: 26765077
[TBL] [Abstract][Full Text] [Related]
6. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T
Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069
[TBL] [Abstract][Full Text] [Related]
7. Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752.
Chen X; Gong L; Ou R; Zheng Z; Chen J; Xie F; Huang X; Qiu J; Zhang W; Jiang Q; Yang Y; Zhu H; Shi Z; Yan X
Gynecol Oncol; 2016 Mar; 140(3):537-44. PubMed ID: 26704638
[TBL] [Abstract][Full Text] [Related]
8. IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer.
Wang D; Xu J; Liu B; He X; Zhou L; Hu X; Qiao F; Zhang A; Xu X; Zhang H; Wicha MS; Zhang L; Shao ZM; Liu S
Cell Death Differ; 2018 Feb; 25(2):330-339. PubMed ID: 29027990
[TBL] [Abstract][Full Text] [Related]
9. Gamma-Secretase Inhibitor IX (GSI) Impairs Concomitant Activation of Notch and Wnt-Beta-Catenin Pathways in CD44
Barat S; Chen X; Cuong Bui K; Bozko P; Götze J; Christgen M; Krech T; Malek NP; Plentz RR
Stem Cells Transl Med; 2017 Mar; 6(3):819-829. PubMed ID: 28186678
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
[TBL] [Abstract][Full Text] [Related]
11. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
12. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
BeLow M; Osipo C
Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
[TBL] [Abstract][Full Text] [Related]
13. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
Zhang CC; Pavlicek A; Zhang Q; Lira ME; Painter CL; Yan Z; Zheng X; Lee NV; Ozeck M; Qiu M; Zong Q; Lappin PB; Wong A; Rejto PA; Smeal T; Christensen JG
Clin Cancer Res; 2012 Sep; 18(18):5008-19. PubMed ID: 22806875
[TBL] [Abstract][Full Text] [Related]
14. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
Zhang S; Chung WC; Miele L; Xu K
Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
[TBL] [Abstract][Full Text] [Related]
15. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
[TBL] [Abstract][Full Text] [Related]
16. ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.
Luke JJ; LoRusso P; Shapiro GI; Krivoshik A; Schuster R; Yamazaki T; Arai Y; Fakhoury A; Dmuchowski C; Infante JR
Cancer Chemother Pharmacol; 2016 Mar; 77(3):549-58. PubMed ID: 26811179
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
Bayet-Robert M; Kwiatkowski F; Leheurteur M; Gachon F; Planchat E; Abrial C; Mouret-Reynier MA; Durando X; Barthomeuf C; Chollet P
Cancer Biol Ther; 2010 Jan; 9(1):8-14. PubMed ID: 19901561
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
19. Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity.
D'Angelo RC; Ouzounova M; Davis A; Choi D; Tchuenkam SM; Kim G; Luther T; Quraishi AA; Senbabaoglu Y; Conley SJ; Clouthier SG; Hassan KA; Wicha MS; Korkaya H
Mol Cancer Ther; 2015 Mar; 14(3):779-787. PubMed ID: 25673823
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Notch signaling pathway enhanced the radiosensitivity of breast cancer cells.
Peng JH; Wang XL; Ran L; Song JL; Zhang ZT; Liu X; Li HY
J Cell Biochem; 2018 Nov; 119(10):8398-8409. PubMed ID: 29904942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
